450 related articles for article (PubMed ID: 33410234)
1. Tryptophan 2,3-dioxygenase in tumor cells is associated with resistance to immunotherapy in renal cell carcinoma.
Sumitomo M; Takahara K; Zennami K; Nagakawa T; Maeda Y; Shiogama K; Yamamoto Y; Muto Y; Nukaya T; Takenaka M; Fukaya K; Ichino M; Sasaki H; Saito K; Shiroki R
Cancer Sci; 2021 Mar; 112(3):1038-1047. PubMed ID: 33410234
[TBL] [Abstract][Full Text] [Related]
2. Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO.
Kim M; Tomek P
Front Immunol; 2021; 12():636081. PubMed ID: 33708223
[TBL] [Abstract][Full Text] [Related]
3. Evaluation and comparison of the commonly used bioassays of human indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO).
Zhang S; Guo L; Yang D; Xing Z; Li W; Kuang C; Yang Q
Bioorg Chem; 2020 Nov; 104():104348. PubMed ID: 33142415
[TBL] [Abstract][Full Text] [Related]
4. Quantification of IDO1 enzyme activity in normal and malignant tissues.
Zhai L; Ladomersky E; Bell A; Dussold C; Cardoza K; Qian J; Lauing KL; Wainwright DA
Methods Enzymol; 2019; 629():235-256. PubMed ID: 31727243
[TBL] [Abstract][Full Text] [Related]
5. Inhibiting tryptophan metabolism enhances interferon therapy in kidney cancer.
Trott JF; Kim J; Abu Aboud O; Wettersten H; Stewart B; Berryhill G; Uzal F; Hovey RC; Chen CH; Anderson K; Graef A; Sarver AL; Modiano JF; Weiss RH
Oncotarget; 2016 Oct; 7(41):66540-66557. PubMed ID: 27572319
[TBL] [Abstract][Full Text] [Related]
6. Discovery and structure-activity relationship studies of 1-aryl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione derivatives as potent dual inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1) and trytophan 2,3-dioxygenase (TDO).
Pan S; Zhou Y; Wang Q; Wang Y; Tian C; Wang T; Huang L; Nan J; Li L; Yang S
Eur J Med Chem; 2020 Dec; 207():112703. PubMed ID: 32871341
[TBL] [Abstract][Full Text] [Related]
7. Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy.
Zhai L; Spranger S; Binder DC; Gritsina G; Lauing KL; Giles FJ; Wainwright DA
Clin Cancer Res; 2015 Dec; 21(24):5427-33. PubMed ID: 26519060
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of novel tryptanthrin derivatives as dual inhibitors of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase.
Li Y; Zhang S; Wang R; Cui M; Liu W; Yang Q; Kuang C
Bioorg Med Chem Lett; 2020 Jun; 30(11):127159. PubMed ID: 32247733
[TBL] [Abstract][Full Text] [Related]
9. Targeting key dioxygenases in tryptophan-kynurenine metabolism for immunomodulation and cancer chemotherapy.
Austin CJ; Rendina LM
Drug Discov Today; 2015 May; 20(5):609-17. PubMed ID: 25478733
[TBL] [Abstract][Full Text] [Related]
10. Targeting Indoleamine Dioxygenase and Tryptophan Dioxygenase in Cancer Immunotherapy: Clinical Progress and Challenges.
Peng X; Zhao Z; Liu L; Bai L; Tong R; Yang H; Zhong L
Drug Des Devel Ther; 2022; 16():2639-2657. PubMed ID: 35965963
[TBL] [Abstract][Full Text] [Related]
11. 4,6-Substituted-1H-Indazoles as potent IDO1/TDO dual inhibitors.
Yang L; Chen Y; He J; Njoya EM; Chen J; Liu S; Xie C; Huang W; Wang F; Wang Z; Li Y; Qian S
Bioorg Med Chem; 2019 Mar; 27(6):1087-1098. PubMed ID: 30773421
[TBL] [Abstract][Full Text] [Related]
12. A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression.
Klar R; Michel S; Schell M; Hinterwimmer L; Zippelius A; Jaschinski F
Cancer Immunol Immunother; 2020 Jan; 69(1):57-67. PubMed ID: 31802183
[TBL] [Abstract][Full Text] [Related]
13. IDO1/TDO dual inhibitor RY103 targets Kyn-AhR pathway and exhibits preclinical efficacy on pancreatic cancer.
Liang H; Li T; Fang X; Xing Z; Zhang S; Shi L; Li W; Guo L; Kuang C; Liu H; Yang Q
Cancer Lett; 2021 Dec; 522():32-43. PubMed ID: 34520819
[TBL] [Abstract][Full Text] [Related]
14. Tryptophan 2,3-Dioxygenase Expression Identified in Murine Decidual Stromal Cells Is Not Essential for Feto-Maternal Tolerance.
Hoffmann D; Dvorakova T; Schramme F; Stroobant V; Van den Eynde BJ
Front Immunol; 2020; 11():601759. PubMed ID: 33363543
[TBL] [Abstract][Full Text] [Related]
15.
Yang D; Zhang S; Fang X; Guo L; Hu N; Guo Z; Li X; Yang S; He JC; Kuang C; Yang Q
J Med Chem; 2019 Oct; 62(20):9161-9174. PubMed ID: 31580660
[TBL] [Abstract][Full Text] [Related]
16. Both IDO1 and TDO contribute to the malignancy of gliomas via the Kyn-AhR-AQP4 signaling pathway.
Du L; Xing Z; Tao B; Li T; Yang D; Li W; Zheng Y; Kuang C; Yang Q
Signal Transduct Target Ther; 2020 Feb; 5(1):10. PubMed ID: 32296044
[TBL] [Abstract][Full Text] [Related]
17. Dual-target inhibitors of indoleamine 2, 3 dioxygenase 1 (Ido1): A promising direction in cancer immunotherapy.
Zhang Y; Hu Z; Zhang J; Ren C; Wang Y
Eur J Med Chem; 2022 Aug; 238():114524. PubMed ID: 35696861
[TBL] [Abstract][Full Text] [Related]
18. High-throughput fluorescence-based screening assays for tryptophan-catabolizing enzymes.
Seegers N; van Doornmalen AM; Uitdehaag JC; de Man J; Buijsman RC; Zaman GJ
J Biomol Screen; 2014 Oct; 19(9):1266-74. PubMed ID: 24870017
[TBL] [Abstract][Full Text] [Related]
19. Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities.
Cheong JE; Sun L
Trends Pharmacol Sci; 2018 Mar; 39(3):307-325. PubMed ID: 29254698
[TBL] [Abstract][Full Text] [Related]
20. Effect of water-immersion restraint stress on tryptophan catabolism through the kynurenine pathway in rat tissues.
Ohta Y; Kubo H; Yashiro K; Ohashi K; Tsuzuki Y; Wada N; Yamamoto Y; Saito K
J Physiol Sci; 2017 May; 67(3):361-372. PubMed ID: 27364617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
